Prostate cell lines

About

Background: Researchers from Stanford University and the University of Washington have developed LuCaP prostate cancer cell lines that have different genetic and biological properties than existing prostate cancer cell lines and provide realistic in vitro models of advanced prostate cancer. In vitro cell culture models provide cost-efficient and reproducible methods for preclinical studies of tumorigenesis and therapeutic development. However, in vitro preclinical models that comprehensively and authentically depict the phenotypes of advanced prostate cancer are lacking. To overcome this the inventors have developed two new human prostate cancer cell lines, LuCaP 136 and LuCaP 147. These cell lines are derived from the LuCaP xenografts developed at the University of Washington which provide invaluable models of advanced prostate cancer for in vivo studies. The cell lines are serially passaged as spheroid cultures, are cryopreserved and will establish xenografts when implanted in immunodeficient mice. The LuCaP 136 and LuCaP 147 cell lines provide a faithful in vitro counterpart to the original xenografts and broaden the opportunities for preclinical therapeutic development. Stage of research: The cell lines have been well characterized and are faithful in vitro counterparts to the original xenografts. For further information please see the publications below.   Applications:   Preclinical model of prostate cancer for: Therapeutic development Drug screening Identification of biomarkers to predict or monitor response to therapy Research Evaluate experimental imaging modalities Study molecular and cellular biology of prostate cancer   Advantages:   In vitro expansion of LuCaP cells is inexpensive and easy compared to in vivo passage Spheroid cultures more closely represent the human situation than 2-dimensional cultures and better predict response to therapeutics Spheroid cultures can be adapted to high-throughput drug screens LuCaP 136 and LuCaP 147 cells have unique genetic characteristics that are not present in other existing prostate cancer cell lines LuCaP cell lines, in contrast to LuCaP xenografts, can easily be genetically engineered and cryopreserved Xenografts can readily be established from cryopreserved LuCaP cell lines